159 related articles for article (PubMed ID: 36726663)
1. When Clinico-Morphological and Molecular Studies Tell Different Stories: A Case of Myelodysplastic Syndrome.
Jain N; Gautam P; Tiwari A; Mittal A; Gupta N; Yadav ML
Int J Appl Basic Med Res; 2022; 12(4):288-290. PubMed ID: 36726663
[TBL] [Abstract][Full Text] [Related]
2. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.
Abou Zahr A; Saad Aldin E; Komrokji RS; Zeidan AM
J Blood Med; 2015; 6():1-16. PubMed ID: 25565910
[TBL] [Abstract][Full Text] [Related]
4. Spectrum of Myelodysplastic Syndrome in Patients Evaluated for Cytopenia(s). A Report from a Reference Centre in Saudi Arabia.
AlMozain N; Mashi A; Alneami Q; Al-Omran A; Bakshi N; Owaidah T; Khalil S; Khogeer H; Hashmi S; Al-Sweedan S; Morris T; AlNounou R
Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):39-44. PubMed ID: 33227261
[TBL] [Abstract][Full Text] [Related]
5. 5q Deletion Myelodysplastic Syndrome in a Young Male Patient.
Elkattawy S; Ayad S; El-Feki I; Guo X; Appiah-Kubi E; Talpur A; Kessler W
Cureus; 2021 Aug; 13(8):e17466. PubMed ID: 34589360
[TBL] [Abstract][Full Text] [Related]
6. The current approach to the diagnosis of myelodysplastic syndromes
Weinberg OK; Hasserjian RP
Semin Hematol; 2019 Jan; 56(1):15-21. PubMed ID: 30573039
[TBL] [Abstract][Full Text] [Related]
7. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
[TBL] [Abstract][Full Text] [Related]
8. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.
Nilsson L; Astrand-Grundström I; Arvidsson I; Jacobsson B; Hellström-Lindberg E; Hast R; Jacobsen SE
Blood; 2000 Sep; 96(6):2012-21. PubMed ID: 10979941
[TBL] [Abstract][Full Text] [Related]
9. Myelodysplastic syndromes/neoplasms: recent classification system based on World Health Organization Classification of Tumors - International Agency for Research on Cancer for Hematopoietic and Lymphoid Tissues.
Gupta G; Singh R; Kotasthane DS; Kotasthane VD
J Blood Med; 2010; 1():171-82. PubMed ID: 22282696
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment.
Acha P; Mallo M; Solé F
Cancers (Basel); 2022 Nov; 14(22):. PubMed ID: 36428627
[TBL] [Abstract][Full Text] [Related]
11. When karyotype is decisive for myelodysplastic syndromes diagnosis.
Perazzio ADSB; Chauffaille MLLF
Hematol Transfus Cell Ther; 2019; 41(4):371-373. PubMed ID: 31395457
[TBL] [Abstract][Full Text] [Related]
12. Childhood myelodysplastic syndrome.
Chatterjee T; Choudhry VP
Indian J Pediatr; 2013 Sep; 80(9):764-71. PubMed ID: 23912822
[TBL] [Abstract][Full Text] [Related]
13. Cytogenetic and comparative genomic hybridization study of Indian myelodysplastic syndromes.
Kawankar N; Jijina F; Ghosh K; Vundinti BR
Cancer Epidemiol; 2011 Aug; 35(4):e1-5. PubMed ID: 21193364
[TBL] [Abstract][Full Text] [Related]
14. [Myelodysplastic syndromes: pathophysiology, clinical and biological features].
Becha M; Braham Jmili N
Ann Biol Clin (Paris); 2015; 73(6):643-56. PubMed ID: 26635046
[TBL] [Abstract][Full Text] [Related]
15. Higher-risk myelodysplastic syndromes with del(5q): does the del(5q) matter?
Gorshein E; Weber UM; Gore S
Expert Rev Hematol; 2020 Mar; 13(3):233-239. PubMed ID: 32067540
[No Abstract] [Full Text] [Related]
16. Cold autoimmune hemolytic anemia with myelodysplastic syndrome: Not just an "Open and Shut case".
Mutreja D; Paliwal G; Mangal V; Biswas AK
Indian J Pathol Microbiol; 2022; 65(1):195-197. PubMed ID: 35074995
[TBL] [Abstract][Full Text] [Related]
17. Novel combinations to improve hematopoiesis in myelodysplastic syndrome.
Syed K; Naguib S; Liu ZJ; Cimmino L; Yang FC
Stem Cell Res Ther; 2020 Mar; 11(1):132. PubMed ID: 32197634
[TBL] [Abstract][Full Text] [Related]
18. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Ximeri M; Galanopoulos A; Klaus M; Parcharidou A; Giannikou K; Psyllaki M; Symeonidis A; Pappa V; Kartasis Z; Liapi D; Hatzimichael E; Kokoris S; Korkolopoulou P; Sambani C; Pontikoglou C; Papadaki HA;
Haematologica; 2010 Mar; 95(3):406-14. PubMed ID: 19773257
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients.
Pellagatti A; Jädersten M; Forsblom AM; Cattan H; Christensson B; Emanuelsson EK; Merup M; Nilsson L; Samuelsson J; Sander B; Wainscoat JS; Boultwood J; Hellström-Lindberg E
Proc Natl Acad Sci U S A; 2007 Jul; 104(27):11406-11. PubMed ID: 17576924
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
